An atypical caspase-independent death pathway for an immunogenic cancer cell line

REGb cell line, a highly immunogenic tumor cell variant isolated from a rat colon cancer, yields regressive tumors when injected into syngeneic hosts. We previously demonstrated that REGb tumor immunogenicity was related to the capacity of releasing dead cells in vivo. Also, in vitro, REGb cell mono...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2002-09, Vol.21 (39), p.6091-6100
Hauptverfasser:	LARMONIER, Nicolas, BILLEREY, Claire, BONNOTTE, Bernard, REBE, Cédric, PARCELLIER, Arnaud, MOUTET, Monique, FROMENTIN, Annie, KROEMER, Guido, GARRIDO, Carmen, SOLARY, Eric, MARTIN, Francois
Format:	Artikel
Sprache:	eng
Schlagworte:	Ageing, cell death Amino Acid Chloromethyl Ketones - pharmacology Animals Annexin A5 - metabolism Apoptosis Apoptosis - physiology Apoptosis Inducing Factor Biological and medical sciences Cancer Caspase Caspase Inhibitors Caspases - metabolism Cell culture Cell death Cell physiology Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Chromatin Chromatin - metabolism Colon cancer Cycloheximide Cycloheximide - pharmacology Cysteine Proteinase Inhibitors - pharmacology Dendritic cells Deoxyribonucleases - metabolism DNA DNA fragmentation Fas Ligand Protein Flavoproteins - metabolism Fundamental and applied biological sciences. Psychology Immune response Immunoblotting Immunogenicity Ligands Membrane Glycoproteins - metabolism Membrane Potentials - physiology Membrane Proteins - metabolism Mitochondria - metabolism Molecular and cellular biology Monomolecular films mRNA Necrosis Nucleosomes - metabolism Plasma Protein biosynthesis Protein synthesis Protein Synthesis Inhibitors - pharmacology Proteins Rats RNA Serum-free medium Tumor Cells, Cultured - drug effects Tumor Cells, Cultured - immunology Tumor Cells, Cultured - pathology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!